New Delhi, March 17 Fake and falsified obesity drugs could be prompting a public health concern driven by high prices, a lack of insurance, and the desire to lose weight, according to a world report article published in The Lancet journal.Author Sophie Cousins, an Australian writer and health...
cardiovascular health
counterfeit drugs
diabetes treatment
drug safety
fdawarning
glp-1 receptor agonists
mexico
mounjaro
obesity drugs
ozempic
pharmaceutical fraud
prescription drugs
public health
united states
weight loss
world health organization